

Curriculum Vitae

Last name, First name: De Jong, Wilhelmus (Wim)

Gender: Male

Nationality: Dutch

Overall Scientific Expertise:

Wim H. De Jong, DVM, PhD has graduated as veterinarian at Utrecht University, the Netherlands in 1978 and is registered as specialist in Experimental Pathobiology, and Toxicological Pathology. He started his career as scientist in experimental oncology studying immunotherapy and drug targeting in animal tumor models, changed to vaccine control and next to safety evaluation of xenobiotics, medical devices and nanomaterials. He is involved in the safety evaluation and risk assessment of xenobiotics, biomaterials/medical devices and nanomaterials, and research in development of alternative methods for safety evaluation. He is/has been a member of various national and international advisory committees and is member of the editorial board and reviewer for several scientific journals.

Professional Experience

Years employed from – to	Title of position	Employer – name and location	Areas of professional specialisation [▲]
1993-present	Senior scientist	Centre for Health Protection, National Institute for Public Health (RIVM), Bilthoven, The Netherlands.	Toxicologic pathology, Safety evaluation medical devices, Nanotoxicology, Immunotoxicology, Nanomaterial Toxicokinetics, Risk assessment.
1990-1992	Senior scientist	Laboratory for Control of Biological Products (RIVM)	Safety and efficacy evaluation paediatric vaccines
1985-1990	Research scientist	Laboratory of Pathology (RIVM)	Immunotherapy and chemotherapy of cancer, drug delivery.
1978-1985	Research fellow	Dutch National Cancer Foundation, Amsterdam, The Netherlands	Immunotherapy of cancer, experimental oncology

Educational Background

Year	Degree awarded	Educational Institution – name and location	Areas of educational specialisation*
1971-1987	DVM	University of Utrecht, Utrecht, The Netherlands	Veterinary Medicine
1985	PhD	University Utrecht, Utrecht, The Netherlands	PhD in Veterinary Medicine

Memberships in Scientific Advisory Bodies/Committees/Panels (if any):

1993- present. Member of several working groups of ISO/CEN TC 194 “Biological and Clinical Evaluation of Medical Devices”, and since 2003 chairman of the WG “Irritation and sensitisation” and co-chair of the recently (2014) established WG “nanomaterials in medical devices”.

From 1997 – 2003 he was member and vice chair of the Scientific Committee on Medicinal Products and Medical Devices, DG Health and Consumer Protection, EC, Brussels, Belgium.

2001 - present. Chairman of CEN TC 206 Biological Evaluation of Medical Devices.

2004- 2013 Vice chair of the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) for which he was both chairman and member of various working groups.

2007-... Member of ISO TC 229 Nanotechnology WG3 Health Safety and the Environment.

Memberships in Learned Societies (if any):

Dutch Society of Immunology, Dutch Society of Pathology, Dutch Society of Biomaterials and Tissue Engineering, Dutch Society of Toxicology.

Memberships in Editorial Boards (if any):

FEMS Immunology and Medical Microbiology (1993-1996), Biomaterials (2002 – present), Expert Reviews of Medical Devices (2004- present), Particle Fibre Toxicology (2011-present), Nanotoxicology (2015-present).

List of Publications:

The research conducted resulted in more than 140 publications in peer reviewed international journals and several book chapters. He was guest editor for a special issue of Methods.

“Animal models in immunotoxicology. Methods 41, 1-1, 2007”.

Specific publications:

Hougaard KS, Campagnolo L, Chavatte-Palmerc P, Tarrade A, Rousseau-Ralliard D, Valentino S, Park MVDZ, De Jong WH, Wolterink G, Piersma AH, Ross BL, Hutchison GR, Stilund Hansen J, Vogel U, Jackson P, Slama R, Pietroiusti A, Cassee FR. A perspective on the developmental toxicity of inhaled nanoparticles. *Reproductive Toxicology* 56, 118-140, 2015.

Van Kesteren PCE, Cubadda F, Bouwmeester H, Van Eijkeren JCH, Dekkers S, De Jong WH, Oomen AG. Novel insights into the risk assessment of the nanomaterial synthetic amorphous silica, additive E551, in food. *Nanotoxicology*, 9, 442-452, 2015. Early on line 1-10, July 2014.

Geraets L, Oomen AG, Krystek P, Jacobsen NR, Wallin H, Laurentie M, Verharen HW, Brandon EFA, De Jong WH. Tissue distribution and elimination after oral and intravenous administration of different titanium dioxide nanoparticles in rats. *Part Fibre Toxicol* 2014;11:30.

Krystek P, Tentschert J, Nia Y, Trouillier B, Noël L, Goetz ME, Papin A, Luch A, Guérin T, De Jong WH. Method development and inter-laboratory comparison about the determination of titanium from titanium dioxide nanoparticles in tissues by inductively coupled plasma mass spectrometry. *Anal Bioanal Chem* 406, 3853-3861, 2014.

De Jong WH, Carraway JW, Geertsma RE. Testing for the biological evaluation of biomaterials and medical devices. In; Boutrand JP (editor) *Biocompatibility and performance of medical devices*. Woodhead Publishing Ltd, Cambridge, UK. 2012 pp 120-158.

De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. *Int J Nanomedicine*, 3, 133-149, 2008.

De Jong WH, Hagens, WI, Krystek P, Burger MC, Sips AJAM, Geertsma RE. Particle size dependent organ distribution of gold nanoparticles after intravenous administration. *Biomaterials* 29, 1912-1919, 2008.